insulin 287
Recombinant proteinexperimental
Clinical trial activity
12 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
9
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Oct 1, 2012 (NCT01730014)
Timeline
Indications
Mechanism of action
- Insulin-like growth factor I receptorSupplementation
IGF1R supplementation
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- insulin 287
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03922750 | Phase 2 | May 9, 2019 | Novo Nordisk |
| NCT03951805 | Phase 2 | May 9, 2019 | Novo Nordisk |
| NCT03945656 | Phase 1 | May 7, 2019 | Novo Nordisk |
| NCT03789578 | Phase 1 | Jan 17, 2019 | Novo Nordisk |
| NCT03766854 | Phase 1 | Dec 7, 2018 | Novo Nordisk |
| NCT03751657 | Phase 2 | Nov 29, 2018 | Novo Nordisk |
| NCT03723772 | Phase 1 | Nov 29, 2018 | Novo Nordisk |
| NCT03723785 | Phase 1 | Nov 9, 2018 | Novo Nordisk |
| NCT02964104 | Phase 1 | Nov 1, 2016 | Novo Nordisk |
| NCT02148861 | Phase 1 | May 1, 2014 | Novo Nordisk |
| NCT01809184 | Phase 1 | Mar 4, 2013 | Novo Nordisk |
| NCT01730014 | Phase 1 | Oct 1, 2012 | Novo Nordisk |
Showing 12 of 12 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Novo Nordisk | For profit | 12 | 12 | 2 | 2012 |
1 organizations
Page 1 / 1